Dr. Taylor Discusses the Toxicities and Impact of Lenvatinib in the SELECT Trial
Matthew H. Taylor, MD, Oregon Health and Science University, discusses the toxicities and impact of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.
Patients tolerated lenvatinib very well, says Taylor. They were able to stay on an average higher dose than those previously treated with a multikinase inhibitor, as well as those naive to treatment.
Taylor says that if patients have already undergone therapy with an anti-VEGF treatment, other than lenvatinib, and they have not responded or tolerated that treatment, then it is very reasonable for these patients to receive lenvatinib and respond well to it.
Matthew H. Taylor, MD, medical oncologist, Oregon Health and Science University, discusses the toxicities, as well as the impact, of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
